Check out this infographic, co-created with @BioanalysisZone which addresses key challenges in AAV analysis that have historically limited gene therapy's potential. >>> https://t.co/5JAjJD1pj3

🔬 How human iPSC models are revolutionizing gene therapy safety testing! In this interview, Saqlain Suleman, a lecturer at Anglia Ruskin University, dives into how human induced pluripotent stem cell (iPSC) models are revolutionizing gene therapy safety testing by offering an

High drug development costs often leave rare diseases like Machado-Joseph disease without treatment options. But what if we could repurpose existing commercial drugs instead of starting from scratch? Here, Frederico Pena from the Center for Neuroscience and Cell Biology, Gene

FREE PromoCell eBook – Discover more on adoptive cell therapies: advancing cancer treatment for solid tumors  Download here >>> https://t.co/ryKaiGoi7f

Our latest feature, created with @BioanalysisZone, explores AAV characterization and analysis for gene therapy with a video, infographic and interview. >>> https://t.co/6Izulzbso8

Our recent webinar with @BioLegend's Kenta Yamamoto broke down the complexities of GMP ancillary material solutions and explored proven strategies for cell therapy manufacturing success. Couldn't make the live session? ▶️Watch the full recording >>> https://t.co/ZqIOdhoogH 💡Or

Can stem cells extracted from the body's fatty tissues be used to treat conditions like osteoporosis? Researchers from @OsakaMetUniv_en have tried >>> https://t.co/Rq1MVsFcTy

Type 2 diabetes is the most prevalent form of diabetes, characterized by insulin resistance in affected individuals. We had a chance to ask An Nisaa from the @UniofNottingham about her research project, which is focused on developing a non-viral, glucose-responsive gene system

Just weeks after releasing positive topline results from its Phase I/II study of AMT-130, uniQure announced that the FDA may no longer consider the data adequate for BLA submission. https://t.co/FWMyXhQykD

Planning your cell therapy manufacturing strategy? Our recent webinar Q&A with @BioLegend's Kenta Yamamoto reveals why prospective cell therapy manufacturers should begin sourcing ancillary materials during early development, not just before GMP production. Read the highlights

Thanks to everyone who joined our webinar on GMP ancillary material solutions for cell therapy manufacturing! @BioLegend's Program Manager of Custom GMP Bioprocessing, Kenta Yamamoto, shared valuable real-world case studies showcasing BioLegend's solutions. Couldn't make the live

How are virus-like particles being used in cancer treatment? We spoke to Canan Bayraktar from the @KocUniveristy Research Center for Translational Medicine about her research project on EGFRvIII-targeted virus-like particles. Read how these virus-like particles “combine the

The FDA has delivered unexpected feedback to uniQure, potentially delaying the approval of its investigational gene therapy for Huntington’s disease. https://t.co/IJDkb6EMhk

Don’t miss out! As part of our latest feature, created in collaboration with our sister site @BioanalysisZone, this infographic explores AAV characterization and analysis for gene therapy. Download today >>> https://t.co/woHfbRP4nD

Check out our latest feature, jointly produced with our sister site @BioanalysisZone: ‘AAV characterization and analysis for gene therapy’ Find out more here>>> https://t.co/WczhhQsEzy

Researchers identified genes that promote neuron regeneration in mice, then used bioinformatics to find drugs that activate these same genes. This led them to thiorphan, a drug previously tested in other conditions, which successfully promoted nerve growth in cultured adult human

Catch up on the latest in cell and gene therapy with our weekly round-up >>> https://t.co/KdoGMZAhlm This week: 👉 Kyverna Therapeutics announced positive interim data from the Phase II clinical trial of its CAR-T therapy KYV-101 👉 Intellia Therapeutics pauses it Phase III

At this year’s 32nd Annual Congress ESGCT, we took a trip around the poster hall and picked out some posters that stood out to us. We had a chance to ask Òscar Garriga, a PhD student at the Vall d'Hebron Institute of Research, some questions about his research on developing an

Want more from our webinar on cell manufacturing with GMP ancillary materials? Our expert Kenta Yamamoto from @BioLegend has answered the audience questions we didn’t have time to address during the live session in this follow-up Q&A. Catch up now >>>

🆕 @UCLH has treated the first UK patient with CAR-T therapy, obe-cel, for MS. This therapy, already FDA and MHRA-approved for acute lymphoblastic leukemia, is now being explored as a potential treatment for multiple sclerosis. Read about it here >>> https://t.co/F2WZ210t3a